Abstract
Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Keywords: calcitriol, cancer, microRNA, vitamin D.
Current Gene Therapy
Title:Vitamin D and miRNAs in Cancer
Volume: 14 Issue: 4
Author(s): Yingyu Ma, Donald L. Trump and Candace S. Johnson
Affiliation:
Keywords: calcitriol, cancer, microRNA, vitamin D.
Abstract: Vitamin D is a steroid hormone that regulates mineral homeostasis, bone metabolism and many other physiological processes. The active metabolite of vitamin D, 1α, 25-dihydroxyvitamin D (1,25D3), has broad spectrum antitumor activities and potentiates the effects of a number of chemotherapeutic agents. 1,25D3 exerts its anti-tumor effects mainly through genomic mechanisms involving the regulation of gene transcription through vitamin D response elements (VDREs). More recently, miRNAs have been shown to be regulated by 1,25D3. miRNAs are short non-coding RNAs that post-transcriptionally modulate the expression of a wide range of genes. Therefore, they have important regulatory roles in the development and progression of many diseases including cancer. This review focuses on the regulation of miRNA expression by 1,25D3 in cancer model systems and the contribution of the regulated miRNAs to the anti-tumor effect of 1,25D3. In addition, the impact of miRNAs on 1,25D3 signaling is discussed.
Export Options
About this article
Cite this article as:
Ma Yingyu, Trump L. Donald and Johnson S. Candace, Vitamin D and miRNAs in Cancer, Current Gene Therapy 2014; 14 (4) . https://dx.doi.org/10.2174/1566523214666140612153537
DOI https://dx.doi.org/10.2174/1566523214666140612153537 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention
Current Topics in Medicinal Chemistry Gastroesophageal Reflux Disease (GERD): Current Agents and Future Perspective
Current Pharmaceutical Design Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Staging of Breast Cancer with 18F-FDG PET and PET/CT
Current Medical Imaging Preparation, Characterization and <i>In Vitro</i> Biological Evaluation of Novel Curcumin Derivatives as Cytotoxic and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Chemo-Radiation Association in Head and Neck Squamous Cell Carcinoma: Evidences and Criticisms
Current Drug Therapy Summary of Information on the Effects of Ionizing and Non-ionizing Radiation on Cytochrome P450 and Other Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Animal Venoms have Potential to Treat Cancer
Current Topics in Medicinal Chemistry Current and Future Challenges in Primary Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography – Computed Tomography in the Evaluation of Gastrointestinal Malignancies
Current Medical Imaging Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Nanocarriers in Improving Chemotherapy of Multidrug Resistant Tumors: Key Developments and Perspectives
Current Pharmaceutical Design Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry